Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 13

of 'Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents'

Acute gefitinib-induced pneumonitis.
Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y
Int J Clin Oncol. 2004;9(5):406.
A 60-year-old woman with non-small cell lung cancer was treated with gefitinib and developed acute pneumonitis on the third day. Pulmonary damage and/or interstitial lung disease (ILD) related to gefitinib was diagnosed clinically and radiographically. Despite the immediate withdrawal of gefitinib and the administration of high-dose steroid, the patient did not fully recover and finally died of respiratory failure on day 22 after gefitinib had commenced. This case cautions us that careful monitoring provides no guarantee of safeguarding patients against ILD caused by gefitinib. We should make the decision to treat patients with gefitinib very carefully until we can elucidate which patients are at high risk and which patients are likely to have a response to this drug.
Department of Clinical Oncology, Saitama Medical School, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama 350-0451, Japan.